LB Pharmaceuticals Inc (LBRX)

LB Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	13.44	13.66	3.53	1.46
Research & Development	8.64	51.17	7.85	1.35
Operating Expenses	22.07	64.83	11.38	2.81
Operating Income	-22.07	-64.83	-11.38	-2.81
Interest Expense	-	-	-4.83	-2.15
Interest & Investment Income	1.42	1.72	0.81	0.07
Other Non Operating Income (Expenses)	1.37	-0.95	16.22	-9.46
EBT Excluding Unusual Items	-19.28	-64.06	0.83	-14.35
Gain (Loss) on Sale of Investments	0.48	0.96	0.33	0
Other Unusual Items	-	-	-7.44	-
Pretax Income	-18.8	-63.1	-6.27	-14.35
Income Tax Expense	0	0	0	0
Net Income	-18.8	-63.1	-6.28	-14.35
Net Income to Common	-18.8	-63.1	-6.28	-14.35
Shares Outstanding (Basic)	25	0	0	0
Shares Outstanding (Diluted)	25	0	0	0
Shares Change (YoY)	10035.57%	0.87%	8.02%	-
EPS (Basic)	-0.74	-250.61	-25.14	-62.09
EPS (Diluted)	-0.74	-250.61	-25.14	-62.09
Free Cash Flow	-23.02	-53.82	-12.12	-2.73
Free Cash Flow Per Share	-0.91	-213.75	-48.55	-11.80
EBITDA	-21.76	-64.74	-11.37	-2.81
D&A For EBITDA	0.32	0.09	0	0
EBIT	-22.07	-64.83	-11.38	-2.81

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q